- ISIN
- US45782T1051
- CUSIP
- 45782T105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 4, 2019
Highlights
- Market Cap
- $49.45M
- Enterprise Value
- $30.30M
- EPS (TTM)
- -$1.56
- Gross Profit (TTM)
- -$108.00K
- EBITDA (TTM)
- -$26.72M
- Year Range
- $1.09 - $3.24
- Target Price
- $22.00
- ROA (TTM)
- -161.13%
- ROE (TTM)
- -211.99%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
INMB Performance Chart
INmune Bio, Inc. (INMB) is up 19.2% since the beginning of the year. At $2 per share, INMB is trading 42.7% below its 52-week high of $3. Investors who bought $1,000 worth of INMB shares 5 years ago would now be looking at an investment worth $81.
Loading charts...
Returns By Period
INmune Bio, Inc. (INMB) has returned 19.23% so far this year and -19.48% over the past 12 months.
INmune Bio, Inc.
- 1D
- -4.12%
- 1M
- 50.00%
- 6M
- 26.53%
- YTD
- 19.23%
- 1Y
- -19.48%
- 3Y*
- -44.53%
- 5Y*
- -39.51%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.79%
- 1M
- 1.13%
- 6M
- 7.71%
- YTD
- 9.79%
- 1Y
- 20.06%
- 3Y*
- 18.60%
- 5Y*
- 11.43%
- 10Y*
- 13.27%
INMB Monthly Returns History
Based on dividend-adjusted daily data since Feb 4, 2019, INMB's average daily return is +0.09%, while the average monthly return is +1.54%. At this rate, an investment would double in approximately 3.8 years.
Historically, 38% of months were positive and 62% were negative. The best month was Jul 2020 with a return of +121.3%, while the worst month was Jun 2025 at -68.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, INMB closed higher 47% of trading days. The best single day was Jul 14, 2020 with a return of +78.0%, while the worst single day was Jun 30, 2025 at -56.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.92% | -18.87% | -12.40% | 26.55% | -1.40% | 15.60% | 14.11% | 19.23% | |||||
| 2025 | 117.56% | -20.96% | -2.74% | 0.64% | -6.11% | -68.70% | 18.18% | -25.64% | 1.97% | -11.59% | -4.92% | -10.34% | -66.60% |
| 2024 | 5.95% | -2.77% | 1.29% | 0.77% | -20.19% | -6.67% | -2.61% | -22.93% | -18.58% | 8.53% | -13.68% | -7.52% | -58.53% |
| 2023 | 35.33% | 10.02% | -31.57% | 12.23% | 4.55% | 19.79% | -5.62% | -5.48% | -16.42% | 7.68% | 29.63% | 19.15% | 77.60% |
| 2022 | -1.08% | -12.78% | -4.32% | -10.69% | -8.24% | 28.12% | 1.47% | -10.03% | -23.17% | 23.71% | -6.78% | -11.33% | -37.84% |
| 2021 | 5.98% | -11.12% | -26.76% | -0.08% | 14.24% | 29.57% | -13.38% | 55.85% | -18.13% | -5.30% | -30.13% | -20.62% | -40.77% |
Benchmark Metrics
INmune Bio, Inc. has an annualized alpha of 4.13%, beta of 1.17, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 04, 2019.
- This stock participated in 175.79% of S&P 500 Index downside but only 56.86% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.13%
- Beta
- 1.17
- R²
- 0.06
- Upside Capture
- 56.86%
- Downside Capture
- 175.79%
Return for Risk
Risk / Return Rank
INMB ranks 36 for risk / return — below 36% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for INmune Bio, Inc. (INMB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| INMB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.86 | ||
| Sortino ratioReturn per unit of downside risk | -2.06 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.29 | -0.27 |
| Calmar ratioReturn relative to maximum drawdown | -0.30 | 2.21 | -2.52 |
| Martin ratioReturn relative to average drawdown | -0.41 | 9.61 | -10.02 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the INmune Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the INmune Bio, Inc. was 95.98%, occurring on Mar 27, 2026. The portfolio has not yet recovered.
The current INmune Bio, Inc. drawdown is 93.32%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -95.98%Mar 2026 | 4y 6mo | — | 4y 10moSep 2021 - now |
COVID crash2020 | -79.91%Mar 2020 | 10mo 13d | 3mo 28d | 1y 2moMay 2019 - Jul 2020 |
2021 bear market2021 | -65.40%May 2021 | 3mo 23d | 3mo 27d | 7mo 20dJan 2021 - Sep 2021 |
2020 bear market2020 | -52.32%Nov 2020 | 3mo 20d | 1mo 29d | 5mo 19dJul 2020 - Dec 2020 |
2019 correction2019 | -16.11%Mar 2019 | 1mo 9d | 24d | 2mo 3dFeb 2019 - Apr 2019 |
Drawdown Indicators
| INMB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.98% | -56.78% | -39.20% |
Max Drawdown (1Y)Largest decline over 1 year | -64.56% | -9.10% | -55.46% |
Max Drawdown (3Y)Largest decline over 3 years | -92.01% | -18.90% | -73.11% |
Max Drawdown (5Y)Largest decline over 5 years | -95.98% | -25.43% | -70.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.32% | -1.24% | -92.08% |
Average DrawdownAverage peak-to-trough decline | -61.00% | -10.71% | -50.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.37% | 2.09% | +45.28% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of INmune Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how INmune Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for INMB in comparison with other companies in the Biotechnology industry. Currently, INMB has a P/B value of 2.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with INMB
Add INmune Bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with INMB